COGT News and Press, Cogent Biosciences Inc Com From 04/12/23

2023-04-12 17:16:26 ET Gainers: Dragonfly Energy Holdings  ( DFLI ) +5% . C4 Therapeutics ( CCCC ) +5% . Sana Biotechnology ( SANA ) +4% . SunPower Corporation ( SPWR ) +3% . Cogent Biosciences ( COGT ) +3% . Losers: ...

2023-03-14 08:45:01 ET Cogent Biosciences press release ( NASDAQ: COGT ): Q4 GAAP EPS of -$0.56. Cash and Cash Equivalents $259.3M R&D Expenses: Research and development expenses were $36.7 million for the fourth quarter of 2022 Net loss was $39.6 million ...

Initiation of APEX Part 2 planned for mid-2023 Updated clinical data from Phase 3 PEAK lead-in in GIST patients expected 1H23 Initial clinical data from Phase 2 SUMMIT trial in NonAdvSM on-track for 2H23 Ended 2022 with $259.3 million in cash; sufficient to fun...

Summary Cogent Biosciences is a biotechnology company focused on developing solutions for complex medical conditions, with a particular focus on Gastrointestinal Stromal Tumors. Bezuclastinib is a promising tyrosine kinase inhibitor that targets KIT exon 17/18 mutations, commonly found ...

Cogent Biosciences ( NASDAQ: COGT ) has filed for a mixed shelf offering of an unspecified amount. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for development and commercial preparation a...

Demonstrate significant progress toward leadership in Systemic Mastocytosis (SM), including mid-year Part 1 results from Phase 2 APEX trial in AdvSM patients and initial clinical data in 2H23 from Phase 2 SUMMIT trial in NonAdvSM patients Rapidly progress bezuclastinib in 2 nd ...

WALTHAM, Mass. and BOULDER, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer will pre...

Summary Cogent Biosciences, Inc. is building momentum around its bezuclastinib compound. FY22 saw a number of positive advancements of the company's pipeline. The price response to these updates hasn't held into the final stages of the year, however. There are multiple inflectio...

Summary Shares have lost three quarters of their value over the past three years but logged a 60% gain in the past 12 months. Qinlock sales are steadily growing in 4th line GIST with potential to see off-label use in earlier lines of therapy given favorable tolerability profile. Vis...

-   89% ORR in TKI-therapy naïve patients; 73% ORR in all evaluable patients with 27-week median follow-up -   Rapid and deep responses seen including first confirmed CR at 20 weeks; 77% of patients with at least 2 cycles of treatment had complete clearance of bon...